Health Canada extends Evkeeza approval to treat HoFH in infants

Ultragenyx Pharmaceutical (NASDAQ:RARE) secured Health Canada approval for Evkeeza in infants as young as 6 months old with homozygous familial hypercholesterolemia (HoFH), significantly expanding the drug's addressable market. This positive regulatory update arrives amidst a challenging period for the company, with its stock down over 25% recently, although it maintains strong liquidity and reported 33% revenue growth over the past year. Despite a recent FDA Complete Response Letter for its UX111 gene therapy, the broader pipeline shows promise, with analysts reiterating positive ratings, presenting a nuanced investment profile for the $2.8 billion biotech.

Analysis

Ultragenyx Pharmaceutical (RARE) presents a complex investment profile marked by positive commercial and regulatory developments juxtaposed with significant market headwinds and a pipeline setback. The company secured a crucial label expansion from Health Canada for Evkeeza, now approved for infants as young as 6 months with homozygous familial hypercholesterolemia, broadening its addressable market. This builds on a strong financial foundation, evidenced by 33% revenue growth over the last twelve months and a robust liquidity position where current assets exceed short-term obligations. However, this positive news is overshadowed by the stock's recent performance, having declined over 25% in the past week to trade near its 52-week low. Furthermore, the U.S. FDA issued a Complete Response Letter for its gene therapy UX111, citing manufacturing and control issues, which introduces a delay of at least six months for resubmission and review. Despite this pipeline uncertainty and a separate note on disappointing interim data for setrusumab, analyst sentiment remains constructive, with seven analysts revising earnings estimates upward and firms like Morgan Stanley and TD Cowen reiterating Overweight/Buy ratings, indicating underlying confidence in the long-term portfolio.

Key Decisions for Investors

• Investors could view the stock's position near a 52-week low as a potential entry point, capitalizing on the disconnect between weak market sentiment and strong fundamentals, including 33% revenue growth and the expanded approval for Evkeeza.
• It is critical to monitor the company's ability to resolve the FDA's Complete Response Letter for UX111 within the anticipated six-month timeline, as this is a key near-term catalyst and any further delays could heighten execution risk.
• Given the conflicting signals, a prudent strategy involves weighing the tangible commercial revenue from the existing portfolio against the binary risks associated with the clinical pipeline, particularly the UX111 and setrusumab programs.